The selective S1PR1 modulator tamuzimod displayed encouraging efficacy and safety data as induction therapy for patients with UC [1]. Prof. Silvio Danese (Vito-Salute San Raffaele University, Italy) presented the long-term extension data of the phase 2 study evaluating tamuzimod. The randomised, double-blind controlled study (NCT05156125) allocated participants with moderately to severely active UC (n=213) 1:1:1 to tamuzimod 60 mg, tamuzimod 30 mg, or a placebo. After 13 weeks, participants with a clinical response (n=95) were eligible for maintenance therapy with the previously assigned treatment. Also, participants on placebo who lost response during the long-term extension were allowed to switch to the open-label extension phase, in which they received 60 mg tamuzimod. âAll efficacy outcomes were based on non-responder imputation,â mentioned Prof. Danese.
At week 52, the clinical remission rates were 50.0% in both tamuzimod arms and 18.2% in the placebo arm (P=0.021; P=0.0078). Endoscopic remission was documented in 46.4% of participants in the 60 mg arm, 43.8% of the participants in the 30 mg arm, and 18.2% of participants in the placebo arm (P=0.076; P=0.032). In addition, endoscopic and histologic remission was observed in 25.0%, 37.5%, and 9.1% of participants in the 60 mg, 30 mg, and placebo arms, respectively (P=0.18; P=0.019). âThe drug was very safe and there were no major adverse events,â according to Prof. Danese. âThis is probably due to the high selectivity of tamuzimod,â he argued.
âMaintenance treatment with either 30 mg or 60 mg tamuzimod was efficacious and well-tolerated for up to 52 weeks, supporting the continued development of tamuzimod as a treatment for patients with UC,â concluded Prof. Danese.
- Sands BE, et al. Gastroenterology. 2024;166:S-240.
- Danese S, et al. Efficacy and safety of tamuzimod in moderately to severely active ulcerative colitis through 52 weeks: phase 2 long-term extension data. LB14, UEG Week 2024, 12â15 October, Vienna, Austria.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Cendakimab meets primary endpoints in eosinophilic oesophagitis Next Article
Exploring zibotentan plus dapagliflozin for cirrhosis »
« Cendakimab meets primary endpoints in eosinophilic oesophagitis Next Article
Exploring zibotentan plus dapagliflozin for cirrhosis »
Table of Contents: UEGW 2024
Featured articles
Tamuzimod delivers promising long-term data in ulcerative colitis
CULTIVATE: Good signal for etrasimod in Crohnâs disease
Online First
Upadacitinib associated with normalisation of HRQoL in UC
Diagnostic accuracy of fluorescence confocal laser microscopy after EUS-TA
New insights into perianal fistulising CD pathogenesis may lead to new therapeutics
TL1A inhibitor tulisokibart shows potential in ulcerative colitis
An accelerated treatment approach may save lives in pancreatic walled-off necrosis
Encouraging results for L-carnitine in non-alcoholic fatty liver disease
LOVE-CD: Vedolizumab yields better outcomes in early than in late CD
Tamuzimod delivers promising long-term data in ulcerative colitis
Cendakimab meets primary endpoints in eosinophilic oesophagitis
How useful is colonoscopy for constipation in young women?
Guar gum alleviates IBS-related constipation in randomised-controlled trial
CULTIVATE: Good signal for etrasimod in Crohnâs disease
Meaningful corticosteroid-sparing effect of mirikizumab in UC
Is FMT a viable option to treat primary C. difficile infections?
Extending ustekinumab dosing interval does not influence drug survival in IBD
TACITO: Does FMT improve ICI plus VEGFR TKI therapy in mRCC?
Related Articles
April 13, 2021
CheckMate 9ER offers RCC new frontline option
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com